Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARCHE: Abemaciclib for ctDNA-positive HR+/HER2- early breast cancer
jRCT2041250130Phase 2Recruiting
- Sponsor
- Nagoya City University
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of abemaciclib in breast cancer, sponsored by Nagoya City University. Primary endpoint: ctDNA clearance rate. Started Dec 2025; status: recruiting.
02
Drugs
abemaciclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on jRCT2041250130.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041250130.